Key clinical point: This real-world study confirms the efficacy and safety of erenumab in patients with migraine associated with extreme unmet needs.
Major finding : Overall, 52.9%, 58.5%, 57.0%, and 58.8% of patients receiving erenumab achieved ≥50% reduction in monthly migraine days at 3, 6, 9, and 12 months, respectively, with significant reductions in the proportion of patients with chronic migraine at all time points compared with baseline ( P < .001). At month 3, 57.3% of patients changed from chronic migraine to episodic migraine. No treatment-related serious adverse events were reported.
Study details: Findings are from a 1-year prospective, real-word study including 140 patients with migraine and previous migraine preventive treatment failures who received ≥1 dose of erenumab.
Disclosures: This study did not receive funding from any source. Several authors declared receiving personal fees for consultancy activities or research support from various sources, and some authors declared no conflicts of interest.
Source: Lanteri-Minet M et al. One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: Results of the French FHU INOVPAIN registry study. J Headache Pain. 2023;24:152 (Nov 8). doi: 10.1186/s10194-023-01680-4